{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:46:37Z","timestamp":1793295997559,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T00:00:00Z","timestamp":1498521600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s11940-017-0463-4","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T01:07:58Z","timestamp":1498525678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":139,"title":["Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?"],"prefix":"10.1007","volume":"19","author":[{"given":"Amy R.","family":"Tso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,27]]},"reference":[{"key":"463_CR1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJMra010917","volume":"346","author":"PJ Goadsby","year":"2002","unstructured":"Goadsby PJ, Lipton RB, Ferrari MD. Migraine\u2014current understanding and treatment. N Engl J Med. 2002;346:257\u201370.","journal-title":"N Engl J Med"},{"key":"463_CR2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1474-4422(10)70005-3","volume":"9","author":"PJ Goadsby","year":"2010","unstructured":"Goadsby PJ, Sprenger T. Current practice and future directions in the management of migraine: acute and preventive. Lancet Neurol. 2010;9:285\u201398.","journal-title":"Lancet Neurol"},{"key":"463_CR3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1749-6632.1990.tb16912.x","volume":"600","author":"PPA Humphrey","year":"1990","unstructured":"Humphrey PPA, Feniuk W, Perren MJ, Beresford IJM, Skingle M, Whalley ET. Serotonin and migraine. Ann N Y Acad Sci. 1990;600:587\u201398.","journal-title":"Ann N Y Acad Sci"},{"key":"463_CR4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archneurpsyc.1938.02270040093005","volume":"39","author":"JR Graham","year":"1938","unstructured":"Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatr. 1938;39:737\u201363.","journal-title":"Arch Neurol Psychiatr"},{"key":"463_CR5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"\u2022\u2022 Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine\u2014a disorder of sensory processing. Physiol Rev. 2017;97:553\u2013622. Comprehensive review of migraine pathophysiology.","journal-title":"Physiol Rev"},{"issue":"10053","key":"463_CR6","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","volume":"388","author":"GBD Disease","year":"2016","unstructured":"Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545\u2013602.","journal-title":"Lancet"},{"key":"463_CR7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jpain.2016.10.005","volume":"18","author":"AD Raval","year":"2017","unstructured":"Raval AD, Shah A. National trends in direct health care expenditures among US adults with migraine: 2004 to 2013. J Pain. 2017;18:96\u2013107.","journal-title":"J Pain"},{"key":"463_CR8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1526-4610.2009.01369.x","volume":"49","author":"J Munakata","year":"2009","unstructured":"Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2009;49:498\u2013508.","journal-title":"Headache"},{"issue":"4","key":"463_CR9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4):644\u201355.","journal-title":"Headache"},{"issue":"6","key":"463_CR10","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478\u201388.","journal-title":"Cephalalgia"},{"key":"463_CR11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s11940-014-0318-1","volume":"16","author":"AR Tso","year":"2014","unstructured":"Tso AR, Goadsby PJ. New targets for migraine therapy. Curr Treat Options Neurol. 2014;16:318.","journal-title":"Curr Treat Options Neurol"},{"key":"463_CR12","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1093\/brain\/aww236","volume":"139","author":"PJ Goadsby","year":"2016","unstructured":"Goadsby PJ. Bench to Bedside Advances in the twenty-first Century for primary headache disorders\u2014migraine treatments for migraine patients. Brain. 2016;139:2571\u20137.","journal-title":"Brain"},{"key":"463_CR13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/298240a0","volume":"298","author":"SG Amara","year":"1982","unstructured":"Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 1982;298:240\u20134.","journal-title":"Nature"},{"key":"463_CR14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/304129a0","volume":"304","author":"MG Rosenfeld","year":"1983","unstructured":"Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J, et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue specific RNA processing. Nature. 1983;304:129\u201335.","journal-title":"Nature"},{"key":"463_CR15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bcp.12618","volume":"80","author":"L Edvinsson","year":"2015","unstructured":"\u2022\u2022 Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015;80:193\u20139. Comprehensive review of CGRP pharmacology.","journal-title":"Br J Clin Pharmacol"},{"key":"463_CR16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/1756285610388343","volume":"3","author":"S Eftekhari","year":"2010","unstructured":"Eftekhari S, Edvinsson L. Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Disord. 2010;3:369\u201378.","journal-title":"Ther Adv Neurol Disord"},{"key":"463_CR17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0006-8993(01)02645-2","volume":"909","author":"M Hou","year":"2001","unstructured":"Hou M, Kanje M, Longmore J, Tajti J, Uddman R, Edvinsson L. 5-HT1B and 5-HT1D receptors in the human trigeminal ganglion: co-localization with calitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res. 2001;909:112\u201320.","journal-title":"Brain Res"},{"key":"463_CR18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0149-7634(96)00023-1","volume":"21","author":"D Rossum Van","year":"1997","unstructured":"Van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev. 1997;21:649\u201378.","journal-title":"Neurosci Biobehav Rev"},{"key":"463_CR19","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1073\/pnas.82.1.248","volume":"82","author":"FA Tschopp","year":"1985","unstructured":"Tschopp FA, Henke H, Petermann JB, Tobler PH, Janzer R, Hokfelt T, et al. Calcitonin gene-related peptide and its binding sites in the human central nervous system and pituitary. Proc Natl Acad Sci U S A. 1985;82:248\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"463_CR20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/30666","volume":"393","author":"LM McLatchie","year":"1998","unstructured":"McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998;393:333\u20139.","journal-title":"Nature"},{"key":"463_CR21","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1210\/edrv-17-5-533","volume":"17","author":"SJ Wimalawansa","year":"1996","unstructured":"Wimalawansa SJ. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev. 1996;17:533\u201385.","journal-title":"Endocr Rev"},{"key":"463_CR22","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/jcbfm.1987.126","volume":"7","author":"L Edvinsson","year":"1987","unstructured":"Edvinsson L, Ekman R, Jansen I, McCulloch J, Uddman R. Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J Cereb Blood Flow Metab. 1987;7:720\u20138.","journal-title":"J Cereb Blood Flow Metab"},{"key":"463_CR23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.410280213","volume":"28","author":"PJ Goadsby","year":"1990","unstructured":"Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183\u20137.","journal-title":"Ann Neurol"},{"key":"463_CR24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33:48\u201356.","journal-title":"Ann Neurol"},{"key":"463_CR25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1468-2982.2005.00836.x","volume":"25","author":"G Juhasz","year":"2005","unstructured":"Juhasz G, Zsombok T, Jakab B, Nemeth J, Szolcsanyi J, Bagdy G. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia. 2005;25:179\u201383.","journal-title":"Cephalalgia"},{"key":"463_CR26","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","volume":"81","author":"E Cernuda-Morollon","year":"2013","unstructured":"Cernuda-Morollon E, Larrosa D, Ramon C, Vega J, Martinez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81:1191\u20136.","journal-title":"Neurology"},{"key":"463_CR27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","volume":"22","author":"LH Lassen","year":"2002","unstructured":"Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54\u201361.","journal-title":"Cephalalgia"},{"key":"463_CR28","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/0333102410368444","volume":"30","author":"JM Hansen","year":"2010","unstructured":"Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30:1179\u201386.","journal-title":"Cephalalgia"},{"key":"463_CR29","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1212\/WNL.0b013e3181b87942","volume":"73","author":"KM Connor","year":"2009","unstructured":"Connor KM, Shapiro RE, Diener HC, Lucas S, Kost J, Fan X, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009;73:970\u20137.","journal-title":"Neurology"},{"key":"463_CR30","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/0333102410388435","volume":"31","author":"H-C Diener","year":"2011","unstructured":"Diener H-C, Barbanti P, Dahlof C, Reuter U, Habeck J, Podhorna J. BI 44370 TA, an oral CGRP antagonist for the acute treatment of migraine attacks: results from a phase II study. Cephalalgia. 2011;31:573\u201384.","journal-title":"Cephalalgia"},{"key":"463_CR31","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1177\/0333102411398399","volume":"31","author":"DJ Hewitt","year":"2011","unstructured":"Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge J, Bachman R, et al. Randomized controlled trial of the CGRP receptor antagonist, MK-3207, in the acute treatment of migraine. Cephalalgia. 2011;31:712\u201322.","journal-title":"Cephalalgia"},{"key":"463_CR32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/0333102413500727","volume":"34","author":"R Marcus","year":"2014","unstructured":"Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34:114\u201325.","journal-title":"Cephalalgia"},{"key":"463_CR33","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","volume":"350","author":"J Olesen","year":"2004","unstructured":"Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350:1104\u201310.","journal-title":"N Engl J Med"},{"key":"463_CR34","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1177\/0333102416653233","volume":"36","author":"T Voss","year":"2016","unstructured":"Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36:887\u201398.","journal-title":"Cephalalgia"},{"key":"463_CR35","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","volume":"83","author":"TW Ho","year":"2014","unstructured":"Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology (Minneap). 2014;83:958\u201366.","journal-title":"Neurology (Minneap)"},{"issue":"22","key":"463_CR36","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1161\/CIRCULATIONAHA.113.002033","volume":"127","author":"IN Foltz","year":"2013","unstructured":"Foltz IN, Karow M, Wasserman SM. Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know. Circulation. 2013;127(22):2222\u201330.","journal-title":"Circulation"},{"issue":"6","key":"463_CR37","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S1474-4422(08)70110-8","volume":"7","author":"A Lutterotti","year":"2008","unstructured":"Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol. 2008;7(6):538\u201347.","journal-title":"Lancet Neurol"},{"key":"463_CR38","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1474-4422(14)70128-0","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, Goadsby PJ, Spierings ELH, Scherer JC, Sweeney SP, Grayzel DS. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study. Lancet Neurol. 2014;13:885\u201392.","journal-title":"Lancet Neurol"},{"key":"463_CR39","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1474-4422(14)70209-1","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, et al. Randomized, double-blind, placebo-controlled, phase II trial of ALD403, an anti-CGRP peptide antibody in the prevention of frequent episodic migraine. Lancet Neurol. 2014;13:1100\u20137.","journal-title":"Lancet Neurol"},{"key":"463_CR40","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1474-4422(15)00249-5","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomized, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1081\u201390.","journal-title":"Lancet Neurol"},{"key":"463_CR41","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(15)00245-8","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings ELH, Diener H-C, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomized, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1091\u2013100.","journal-title":"Lancet Neurol"},{"key":"463_CR42","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","volume":"15","author":"H Sun","year":"2016","unstructured":"Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, et al. A randomised, double-blind, placebo-controlled, phase 2 study to evaluate the efficacy and safety of AMG 334 for the prevention of episodic migraine. Lancet Neurol. 2016;15:382\u201390.","journal-title":"Lancet Neurol"},{"issue":"4","key":"463_CR43","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","volume":"94","author":"FA Russell","year":"2014","unstructured":"Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94(4):1099\u2013142.","journal-title":"Physiol Rev"},{"issue":"9","key":"463_CR44","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.tips.2016.06.002","volume":"37","author":"A MaassenVanDenBrink","year":"2016","unstructured":"\u2022 MaassenVanDenBrink A, Meijer J, Villalon CM, Ferrari MD. Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci. 2016;37(9):779\u201388. Summary of cardiovascular and cerebrovascular effects of CGRP.","journal-title":"Trends Pharmacol Sci"},{"key":"463_CR45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1212\/WNL.0000000000002801","volume":"87","author":"ME Bigal","year":"2016","unstructured":"Bigal ME, Dodick DW, Krymchantowski AV, VanderPluym JH, Tepper SJ, Aycardi E, et al. TEV-48125 for the preventive treatment of chronic migraine\u2014efficacy at early time points. Neurology (Minneap). 2016;87:41\u20138.","journal-title":"Neurology (Minneap)"},{"issue":"24","key":"463_CR46","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/BF01466734","volume":"52","author":"K Felgenhauer","year":"1974","unstructured":"Felgenhauer K. Protein size and cerebrospinal fluid composition. Klin Wochenschr. 1974;52(24):1158\u201364.","journal-title":"Klin Wochenschr"},{"issue":"6","key":"463_CR47","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","volume":"12","author":"SJ Pittock","year":"2013","unstructured":"Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12(6):554\u201362.","journal-title":"Lancet Neurol"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-017-0463-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-017-0463-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-017-0463-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T01:08:44Z","timestamp":1589764124000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-017-0463-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,27]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["463"],"URL":"https:\/\/doi.org\/10.1007\/s11940-017-0463-4","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,27]]},"article-number":"27"}}